|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil. |
| 公司地址
| 419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560 |
| 電話號碼
| +1 919 328-4400 |
| 傳真號碼
| +1 919 328-4402 |
| 公司網頁
| https://www.liquidia.com |
| 員工數量
| 170 |
| Ms. Dana Boyle |
Chief Accounting Officer |
-- |
05/03/2026 |
| Dr. Roger A. Jeffs, PhD |
Chief Executive Officer and Director |
美元 800.00K |
05/03/2026 |
| Mr. Jason Adair |
Chief Business Officer |
-- |
25/04/2025 |
| Mr. Michael Kaseta |
Chief Operating Officer and Chief Financial Officer |
美元 572.96K |
05/03/2026 |
| Dr. Rajeev Saggar |
Chief Medical Officer |
-- |
25/04/2025 |
| Mr. Russell Schundler |
General Counsel and Secretary |
美元 477.00K |
25/04/2025 |
| Mr. Scott Moomaw |
Chief Commercial Officer |
-- |
25/04/2025 |
|
|
| Mr. Arthur S. Kirsch |
Independent Director |
05/03/2026 |
| Dr. Roger A. Jeffs, PhD |
Chief Executive Officer and Director |
05/03/2026 |
| Mr. David E. Johnson |
Independent Director |
05/03/2026 |
| Dr. Stephen Bloch,M.D. |
Chairman of the Board |
05/03/2026 |
| Mr. Paul B. Manning |
Independent Director |
05/03/2026 |
| Mr. Damian deGoa |
Independent Director |
05/03/2026 |
| Dr. Joanna Horobin, MB.Ch.B. |
Independent Director |
05/03/2026 |
| Mr. Ramandeep Singh |
Independent Director |
05/03/2026 |
| Ms. Katherine Rielly-Gauvin |
Independent Director |
05/03/2026 |
|
|
|
|
